Tafinlar and Epilepsy - a phase IV clinical study of FDA data

Summary:

Epilepsy is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Mekinist, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Epilepsy when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Epilepsy?

Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures) is found to be associated with 1,166 drugs and 1,779 conditions by eHealthMe. Check the latest studies of Epilepsy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 69 people (0.42%) have Epilepsy.

Among these 69 people:

How long have people been on Tafinlar when they have Epilepsy? *

What is the gender of people who have Epilepsy when taking Tafinlar? *

female: 42.65 %
male: 57.35 %

What is the age of people who have Epilepsy when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

What are other side effects people have besides Epilepsy? *

Fever: 27 people, 39.13%
Metastases To Central Nervous System (cancer spreads to central nervous system): 24 people, 34.78%
Malignant Neoplasm Progression (cancer tumour came back): 19 people, 27.54%
Diarrhea: 16 people, 23.19%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 13 people, 18.84%
Weakness: 12 people, 17.39%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 15.94%
General Physical Health Deterioration (weak health status): 11 people, 15.94%
Dizziness: 10 people, 14.49%
High Blood Pressure: 9 people, 13.04%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 36 people, 52.17%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 35 people, 50.72%
High Blood Pressure: 16 people, 23.19%
Oedema (fluid collection in tissue): 6 people, 8.70%
Muscle Spasms (muscle contraction): 5 people, 7.25%
Xerosis (abnormal dryness of the skin or mucus membranes): 5 people, 7.25%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 5.80%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 4 people, 5.80%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 5.80%
Pneumonia: 4 people, 5.80%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Epilepsy?

- Check whether Epilepsy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Epilepsy treatments and more:

Epilepsy (129,286 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Epilepsy:

Epilepsy (1,166 drugs)

Browse all the conditions that are associated with Epilepsy:

Epilepsy (1,779 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.